Latest Articles and Analysis

For a long time, I thought advocacy meant surviving the next appointment. I thought it meant learning how to explain my pain better, how to prepare for another referral visit, how to justify why I...

New Phase 3 data show a single-tablet regimen of bictegravir/lenacapavir could finally bring one-pill simplicity to long-term HIV survivors locked into complex regimens by decades of drug resistance. The science is closing the treatment gap. Will our policy systems do the same?

Rising employer premiums averaging 9.5% erode wages, forcing workers to delay care.

ADAPs achieve 87% viral suppression but face funding crisis as multiple policies erode 340B rebates.

Break Up Big Medicine Act would force structural separation of insurers, PBMs, and pharmacies.

Medicare drug negotiation's third wave includes Biktarvy, raising HIV treatment access concerns.

FY2026 preserves HIV funding but level funding can't support long-acting therapeutics or growing needs.

340B program drifted from patient benefit; federal reform needed for transparency and accountability.

Senate HELP Committee hearing reveals how 340B drug program expansion reflects hospital business strategy rather than patient benefit.

Congressional Budget Office confirms 340B program expansion driven by hospital exploitation rather than pharmaceutical price inflation.

Most Favored Nation pricing threatens to import restrictive QALY-based frameworks that discriminate against expensive treatments.

HRSA clarifies 340B eligibility for STI clinics while manufacturers challenge Ryan White program participation.

HRSA's 340B pilot program replicates existing successful models rather than addressing structural program exploitation.

340B program expansion drains billions from state Medicaid budgets while failing to deliver promised drug cost savings.

CMS draft guidance on 340B claims modifiers creates ambiguity and enforcement gaps threatening program integrity and beneficiary access.

Pharmacy benefit managers extract billions while adding no value, increasing costs without improving patient access or health outcomes.

Trump administration's contradictory drug pricing policies undermine goals of affordability and innovation incentives.

State Prescription Drug Affordability Boards limit public input while basing pricing decisions on flawed methodologies.

FTC investigation confirms pharmacy benefit managers extracted billions in excess revenue through specialty drug markup schemes.

Federal policy failures on copay accumulator programs restrict patient assistance benefits.